カンザス州における心血管疾患の臨床試験
カンザス州内の拠点で、心血管疾患に関する18件の研究が参加者を募集しています。
カンザス州内の都市
公式研究テキスト（英語）
ELEVATE-HFpEF Clinical Study
- University of Kansas Medical Center, Kansas City
被験者募集中
40歳以上 · 全性別 · 2026/10/02更新 · NCT06678841EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
- AMR El Dorado, El Dorado
- Cotton O'Neil Diabetes & Endocrinology Center, Topeka
- Tekton Research - Wichita, Wichita
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07064473Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
- Midwest Heart and Vascular Specialists, Overland Park
- Kansas Nephrology Physicians, PA, Wichita
被験者募集中第4相
18歳以上 · 全性別 · 2026/09/28更新 · NCT06909565Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
- Clinical Trial Site, Hutchinson
- Clinical Trial Site, Kansas City
- Clinical Trial Site, Topeka
- 他2件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/18更新 · NCT07181109Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
- University of Kansas Medical Center, Kansas City
被験者募集中
18歳以上 · 全性別 · 2026/09/15更新 · NCT03242642Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
- The University Of Kansas Medical Center, Kansas City
被験者募集中
18歳〜100歳 · 全性別 · 2026/09/09更新 · NCT06310031An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
- University of Kansas Hospital, Kansas City
- Cotton O Neil Clinical Res Center, Topeka
被験者募集中第3相
18歳〜100歳 · 全性別 · 2026/09/04更新 · NCT07517263A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
- Clinical Research Site, Kansas City
被験者募集中第2相
18歳〜85歳 · 全性別 · 2026/09/02更新 · NCT07333183Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
- University of Kansas Medical Center, Kansas City
- VA Eastern Kansas Healthcare System, Topeka
被験者募集中第4相健康なボランティア歓迎
75歳以上 · 全性別 · 2026/09/01更新 · NCT04262206A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
- Research Site, Kansas City
- Research Site, Kansas City
- Research Site, Topeka
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/24更新 · NCT07000357OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
- Hutchinson Clinic PA, Hutchinson
- University of Kansas Medical Center, Kansas City
- Midwest Heart and Vascular Specialists, Overland Park
被験者募集中第3相
50歳〜105歳 · 全性別 · 2026/08/21更新 · NCT07136012Global Paradise System US Post Approval Study
- Ascension via Christi St. Francis, Wichita
被験者募集中観察研究
18歳以上 · 全性別 · 2026/08/12更新 · NCT06297291The Oxford Risk Factors And Non-Invasive Imaging Study
- Midwest Heart & Vascular Specialists LLC, Kansas City
- St Luke's Hospital, Kansas City
被験者募集中観察研究
18歳〜99歳 · 全性別 · 2026/07/31更新 · NCT05169333PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
- University of Kansas Medical Center (KUMC), Kansas City
被験者募集中
18歳以上 · 全性別 · 2026/06/29更新 · NCT05934487Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
- Kansas University Medical Center, Kansas City
被験者募集中
18歳以上 · 全性別 · 2026/06/10更新 · NCT06526195Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial
- Midwest Heart and Vascular Specialists, Overland Park
被験者募集中第3相
35歳〜80歳 · 全性別 · 2026/04/16更新 · NCT07293260Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
- University of Kansas Medical Center, Kansas City
被験者募集中第1/2相
35歳〜65歳 · 全性別 · 2025/06/08更新 · NCT04715022ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。